NeoGenomics, Inc. has recently released its 10-Q report, providing a detailed insight into its financial performance and operations. NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom, offering testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. The company operates through two segments: Clinical Services and Advanced Diagnostics, providing a wide range of testing services including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, molecular testing, and morphologic analysis.
In its 10-Q report, NeoGenomics reported a net revenue of $181.3 million for the three months ended June 30, 2025, compared to $164.5 million for the same period in 2024. For the six months ended June 30, 2025, the company reported net revenue of $349.4 million, up from $320.7 million in the same period last year. The cost of revenue for the three months ended June 30, 2025, was $104.1 million, while the gross profit was reported at $77.3 million.
The company's loss from operations for the three months ended June 30, 2025, was $47.6 million, compared to a loss of $21.9 million for the same period in 2024. For the six months ended June 30, 2025, the loss from operations was $75.5 million, compared to $52.5 million in the same period last year. NeoGenomics reported a net loss of $45.1 million for the three months ended June 30, 2025, and a net loss of $71 million for the six months ended June 30, 2025.
The company's condensed consolidated balance sheet as of June 30, 2025, showed total assets of $1.39 billion, with current assets amounting to $392.6 million and non-current assets totaling $1.0 billion. The total liabilities and stockholders' equity were reported at $1.39 billion.
NeoGenomics' cash and cash equivalents as of June 30, 2025, were $154.7 million, down from $367 million as of December 31, 2024. The company reported a net cash used in operating activities of $5 million for the six months ended June 30, 2025.
The company's stockholders' equity as of June 30, 2025, was $854 million, compared to $902.3 million as of December 31, 2024.
These figures provide a snapshot of NeoGenomics' financial performance and position, reflecting the company's ongoing operations and financial health as detailed in its 10-Q report. Following these announcements, the company's shares moved -20.12%, and are now trading at a price of $5.16. If you want to know more, read the company's complete 10-Q report here.
